Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Bremelanotide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 322,960Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Palatin Reports Positive Results From Phase 2 Obesity Study
    Palatin Reports Positive Results From Phase 2 Obesity Study

    17 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-reports-positive-appetite-suppression-results-from-phase-2-obesity-study-of-mc4r-agonist-bremelanotide-and-tirzepatide-302431194.html

    PR NEWSWIRE
    17 Apr 2025
    Share Share
    Palatin's Bremelanotide with Tirzepatide Meets Phase 2 Goal
    Palatin's Bremelanotide with Tirzepatide Meets Phase 2 Goal

    31 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1gip-tirzepatide-meets-primary-endpoint-in-phase-2-obesity-study-302414708.html

    PR NEWSWIRE
    31 Mar 2025
    Share Share
    Palatin Complete Ph 2 Obesity Study with Bremelanotide & Tirzepatide
    Palatin Complete Ph 2 Obesity Study with Bremelanotide & Tirzepatide

    06 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-completes-phase-2-obesity-study-with-mc4r-bremelanotide-plus-glp-1gip-tirzepatide-302369916.html

    PR NEWSWIRE
    06 Feb 2025
    Share Share
    Palatin Completes Enrollment in Bremelanotide Obesity Study
    Palatin Completes Enrollment in Bremelanotide Obesity Study

    31 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist-co-administered-with-tirzepatide-glp-1gip-for-the-treatment-of-obesity-302292542.html

    PR NEWSWIRE
    31 Oct 2024
    Share Share
    Palatin Doses First Patient In Bremelanotide-Tirzepatide Obesity Trial
    Palatin Doses First Patient In Bremelanotide-Tirzepatide Obesity Trial

    23 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/first-patient-dosed-in-phase-2-clinical-study-of-palatins-bremelanotide-co-administered-with-tirzepatide-glp-1-for-the-treatment-of-obesity-302228157.html

    PR NEWSWIRE
    23 Aug 2024
    Share Share
    Palatin Begins Phase 2 Study Of Bremelanotide With PDE5i For ED Treatment
    Palatin Begins Phase 2 Study Of Bremelanotide With PDE5i For ED Treatment

    20 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-announces-the-initiation-of-a-phase-2-clinical-study-of-bremelanotide-co-administered-with-a-pde5i-for-the-treatment-of-erectile-dysfunction-ed-302177672.html

    PR NEWSWIRE
    20 Jun 2024
    Share Share